A Randomized Phase 2 Trial of a Preparative Regimen of Bortezomib, High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid
Cancer - United States
doi 10.1002/cncr.26517
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2011
Authors
Publisher
Wiley